These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 18191004)

  • 1. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
    Lokugamage KG; Yoshikawa-Iwata N; Ito N; Watts DM; Wyde PR; Wang N; Newman P; Kent Tseng CT; Peters CJ; Makino S
    Vaccine; 2008 Feb; 26(6):797-808. PubMed ID: 18191004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
    Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N
    Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two palmitylated cysteine residues of the severe acute respiratory syndrome coronavirus spike (S) protein are critical for S incorporation into virus-like particles, but not for M-S co-localization.
    Ujike M; Huang C; Shirato K; Matsuyama S; Makino S; Taguchi F
    J Gen Virol; 2012 Apr; 93(Pt 4):823-828. PubMed ID: 22238235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
    Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
    Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
    J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
    Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
    Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
    Liu RY; Wu LZ; Huang BJ; Huang JL; Zhang YL; Ke ML; Wang JM; Tan WP; Zhang RH; Chen HK; Zeng YX; Huang W
    Virus Res; 2005 Sep; 112(1-2):24-31. PubMed ID: 16022898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
    Ba L; Yi CE; Zhang L; Ho DD; Chen Z
    Appl Microbiol Biotechnol; 2007 Oct; 76(5):1131-6. PubMed ID: 17581748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
    Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S
    Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein.
    Yao YX; Ren J; Heinen P; Zambon M; Jones IM
    J Infect Dis; 2004 Jul; 190(1):91-8. PubMed ID: 15195247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles.
    Siu YL; Teoh KT; Lo J; Chan CM; Kien F; Escriou N; Tsao SW; Nicholls JM; Altmeyer R; Peiris JS; Bruzzone R; Nal B
    J Virol; 2008 Nov; 82(22):11318-30. PubMed ID: 18753196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
    Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
    Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice.
    Yan K; Tan W; Wang H; Wang Y; Zhang X; Li Y; Ruan L
    Viral Immunol; 2009 Feb; 22(1):57-66. PubMed ID: 19210229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
    Li J; Ulitzky L; Silberstein E; Taylor DR; Viscidi R
    Viral Immunol; 2013 Apr; 26(2):126-32. PubMed ID: 23573979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.